Cochrane · systematic review · CD011066
Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase
Scheffers, CS, Armstrong, S, Cantineau, AEP, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 7 · 50%Low 1 · 7.1%Moderate 3 · 21.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase
Population: women in the peri‐ or postmenopausal phase
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL, wellbeing (end scores) (sensitivity analysis) different scales for quality of life (QoL) DHEA vs control (placebo or no treatment) | no estimate extracted | 8 studies · 287 participants | Moderate Downgraded: imprecision |
Side effects (androgenic overall combined with acne) number of events DHEA vs control (placebo or no treatment) | OR 3.77 [1.36, 10.47] | 5 studies · 250 participants | Moderate Downgraded: imprecision |
Side effects ‐ androgenic side effects number of events DHEA vs control (placebo or no treatment) | OR 6.57 [1.37, 31.59] | 1 study · 92 participants | Low Downgraded: imprecision |
Side effects ‐ acne number of events DHEA vs control (placebo or no treatment) | OR 2.26 [0.56, 9.02] | 4 studies · 158 participants | Moderate Downgraded: imprecision |
Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase
Population: Women in the peri‐ or postmenopausal phase
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL, wellbeing (change scores) ‐ oral administration Oral DHEA vs control subgrouped by differing routes of administration | no estimate extracted | 1 study · 66 participants | Very low Downgraded: risk of bias |
QoL, wellbeing (change scores) ‐ intravaginal application Oral DHEA vs control subgrouped by differing routes of administration | no estimate extracted | 1 study · 107 participants | Very low Downgraded: risk of bias |
Side effects: acne ‐ skin application Oral DHEA vs control subgrouped by differing routes of administration | OR 2.74 [0.1, 74.87] | 1 study · 22 participants | Very low Downgraded: risk of bias |
Side effects: acne ‐ oral administration Oral DHEA vs control subgrouped by differing routes of administration | OR 2.16 [0.47, 9.96] | 3 studies · 136 participants | Very low Downgraded: risk of bias |
DHEA versus HT for women in the peri‐ or postmenopausal phase
Population: Women in the peri‐ or postmenopausal phase
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL, general wellbeing DHEA versus ET DHEA vs HT | no estimate extracted | 1 study · 17 participants | Very low |
QoL, general wellbeing DHEA versus ET + P DHEA vs HT | no estimate extracted | NR | No studies |
QoL, general wellbeing DHEA versus tibolone DHEA vs HT | no estimate extracted | NR | No studies |
Acne DHEA versus ET DHEA vs HT | OR 17 [0.9, 320.37] | 1 study · 50 participants | Very low |
Acne DHEA versus tibolone DHEA vs HT | OR 17 [0.9, 320.37] | 1 study · 50 participants | Very low Downgraded: risk of bias |
Acne DHEA versus ET + P DHEA vs HT | no estimate extracted | NR | No studies |